September 24, 2018

ALEXANDRIA, Va. – New studies released today reveal the financial difficulties that people living with cancer currently face. The research looks at financial distress, also known as “financial toxicity,” among patients with metastatic breast cancer and older patients, as well as conversations about cost of care that women with breast cancer are having with their physicians. Authors will present their findings at the American Society of Clinical Oncology’s (ASCO) upcoming Quality Care Symposium, taking place September 28–29, in at the JW Marriott Phoenix Desert Ridge in Phoenix.

September 24, 2018

ALEXANDRIA, Va. – In the midst of the national opioid epidemic, two new studies explore opioid use in cancer care. The studies compared opioid deaths among cancer patients to the general population and looked at an initiative to reduced opioid use after oncology surgeries. Authors will present their findings at the American Society of Clinical Oncology’s (ASCO) upcoming Quality Care Symposium, taking place September 28–29, in at the JW Marriott Phoenix Desert Ridge in Phoenix.

September 13, 2018

The American Society of Clinical Oncology (ASCO) today issued a set of recommendations for overcoming financial barriers to patient participation in cancer clinical trials. ASCO’s policy statement, “Addressing Financial Barriers to Patient Participation in Clinical Trials,” stresses the importance of increasing participation in clinical research, especially for patients from particular ethnic/racial, geographic, age, socioeconomic, and other underserved demographic subgroups.

September 12, 2018

ALEXANDRIA, Va. — The number of international practices certified in delivering high-quality cancer care based on rigorous standards established by the American Society of Clinical Oncology (ASCO) is increasing. The Medisprof Cancer Center in Romania joins six other practices in Brazil, Greece, and Spain in achieving ASCO’s Quality Oncology Practice Initiative (QOPI®) Certification.

September 11, 2018

Alexandria, Va. – The American Society of Clinical Oncology (ASCO) warns that certain provisions of the 2019 Medicare Physician Fee Schedule (MPFS) proposed rule will undermine  access to cancer care for Medicare beneficiaries through a combination of payment reductions under the MPFS. In a detailed comment letter to the Centers for Medicare & Medicaid Services (CMS), ASCO fully outlines its concerns with the proposal and recommends specific steps be taken to ensure changes proposed in the rule do not endanger Medicare beneficiary access to cancer care.

September 6, 2018

Alexandria, Va. — CancerLinQ LLC, a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology (ASCO®), has announced that Stanford Health Care has signed an agreement to participate in the CancerLinQ® platform. Stanford Health Care includes Stanford Cancer Institute which is designated as a Comprehensive Cancer Center by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH). 

August 31, 2018

Senator John McCain will lie in state in the U.S. Capitol Building today. The following ASCO statement pays tribute to his life-long service to our country.

August 30, 2018

Alexandria, Va. —In a new position statement, the American Society of Clinical Oncology (ASCO) warns that some of the practices of pharmacy benefit manager (PBM) companies use could hinder patient access to timely, high-quality cancer care. ASCO describes a range of PBM practices that, while they may be intended to help control costs in cancer care, might compromise physicians’ ability to provide the right treatment at the right time for people with cancer. 

August 28, 2018

ALEXANDRIA, Va. – CancerLinQ LLC announced today that Integra Connect’s EHR Solution for Oncology has been recognized as the first CancerLinQ® Certified Electronic Health Record (EHR) System. CancerLinQ LLC is a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology (ASCO) that oversees the development and operation of CancerLinQ®, a health information technology platform working to improve quality and value of care for all patients by connecting cancer care team members, researchers, and sponsors with real-world cancer data. In addition, CancerLinQ and Integra Connect have entered into an agreement to collaborate on products and services geared toward improving the quality of cancer care and the access of the CancerLinQ® platform to oncology practices.

August 22, 2018

Alexandria, Va. — CancerLinQ LLC, a wholly-owned nonprofit subsidiary of the American Society of Clinical Oncology (ASCO), has brought on technology collaborators Concerto HealthAI and Tempus to accelerate its joint research effort with the Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER) aimed at understanding the real-world use, tolerability, and effectiveness of immune checkpoint inhibitors. Concerto HealthAI and Tempus have begun to assist in the analysis of a de-identified data set that CancerLinQ has provided to the FDA, representing more than 10,000 patients who have been treated with immune checkpoint inhibitors for both approved and unapproved indications.

August 22, 2018

Alexandria, VA – Advanced practice providers (APPs) have increasingly become integral members of the oncology care delivery team, according to the first large-scale study of nurse practitioners (NPs) and physician assistants (PAs) in oncology published today in the Journal of Oncology Practice. The “Understanding the Role of Advanced Practice Providers in the U.S.” study was conducted as a collaboration of the American Society of Clinical Oncology (ASCO), the American Academy of PAs (AAPA), the Association of Physician Assistants in Oncology (APAO), the Advanced Practitioner Society for Hematology and Oncology (APSHO), and the Oncology Nursing Society (ONS).

August 16, 2018

Alexandria, Va. – The American Society of Clinical Oncology (ASCO) warns that Medicaid work requirements may hinder patients’ access to essential cancer care and reduce the already limited time physicians are able to spend with their patients. In a new position statement released today, ASCO also recommends that federal and state policymakers take specific steps to ensure that new Medicaid requirements will not harm patients with cancer.  

 

August 10, 2018

ALEXANDRIA, Va.  Cory Wiegert has been named Chief Executive Officer (CEO) of CancerLinQ LLC, a wholly owned non-profit subsidiary of the American Society of Clinical Oncology (ASCO). Mr. Wiegert, a proven expert in building and successfully launching innovative technology solutions, will begin his new role on August 13, 2018, overseeing the continued expansion and implementation of the CancerLinQ® platform.

August 9, 2018

WASHINGTON, D.C. -- The American Society of Clinical Oncology, Inc. (ASCO®) and Friends of Cancer Research (Friends) have submitted to the Food and Drug Administration (FDA) recommended language for five guidance documents on ways to broaden eligibility criteria for cancer clinical trials. The recommendations are part of an ASCO and Friends collaboration to broaden eligibility for participating in clinical trials by addressing five specific areas: minimum age requirements for trial enrollment, HIV/AIDS status, brain metastases, organ dysfunction, and prior and concurrent malignancies.

August 8, 2018

ASCO strongly opposes the Centers for Medicare & Medicaid Services (CMS) decision to allow Medicare Advantage plans to employ step therapy across physician-administered and self-administered drugs under Medicare Part B and Part D.

Pages